FBC
EW icon

Fairfield, Bush & Co’s Edwards Lifesciences EW Stock Holding History

Fairfield, Bush & Co’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-40
Closed -$4K – 221
2022
Q2 		$4K Buy
+40
New +$4.14K ﹤0.01% 364

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fairfield, Bush & Co's EW Position: Q3 2022 in Review

Fairfield, Bush & Co sold out of Edwards Lifesciences (EW) in Q3 2022, closing a stake of 40 shares — an estimated $4K sold.

Fairfield, Bush & Co first reported a position in EW in Q2 2022 and held it in 1 quarter. The position peaked at $4K in Q2 2022. 1,246 funds tracked by Wall St. Rank hold EW as of Q3 2022.

  • Fairfield, Bush & Co reported no remaining Edwards Lifesciences position as of Q3 2022 after selling out during the quarter.
  • Fairfield, Bush & Co sold 40 Edwards Lifesciences shares in Q3 2022, an estimated $4K.
  • Fairfield, Bush & Co first reported a position in Edwards Lifesciences in Q2 2022 and held it in 1 quarter.
  • Fairfield, Bush & Co's Edwards Lifesciences position peaked at $4K in Q2 2022.
  • 1,246 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2022.

Based on Fairfield, Bush & Co's 13F filing for Q3 2022, filed 7 Nov 2022.